Search results
Pages
-
- Patterns of axillary staging and management in clinically node positive breast cancer patients treated with neoadjuvant systemic therapy
-
- Reply to: sentinel node biopsy after neoadjuvant chemotherapy for breast cancer in patients with pre-treatment node-positive: recommendation to optimize the performance
-
- Strong CD8+lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy
-
- Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer
-
- Reliability of Self-reported Treatment Data by Patients With Breast Cancer Compared With Medical Record Data
-
- Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer
-
- A prospective comparison of younger and older patients' preferences for breast-conserving surgery versus mastectomy in early breast cancer
-
- Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe
-
- Treatment recommendations for older women with breast cancer: A survey among surgical, radiation and medical oncologists
-
- HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2
-
- Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients: Results from the TEAMIIA study (BOOG2006-04)
-
- Importance of patient reported outcome measures versus clinical outcomes for breast cancer patients evaluation on quality of care
-
- The clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population: a FOCUS study analysis
-
- The influence of insulin-like Growth Factor-1-Receptor expression and endocrine treatment on clinical outcome of postmenopausal hormone receptor positive breast cancer patients: A Dutch TEAM substudy analysis
-
- The clinical prognostic value of molecular intrinsic tumor subtypes in older breast cancer patients: A FOCUS study analysis
-
- Vitamin D (25-0H D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: Data from the NEOZOTAC trial (BOOG 10-01)
-
- Variations in compliance to quality indicators by age for 41,871 breast cancer patients across Europe: A European Society of Breast Cancer Specialists database analysis
-
- Long term effects of extended adjuvant endocrine therapy on quality of life in breast cancer patients
-
- Disorganised stroma determined on pre-treatment breast cancer biopsies is associated with poor response to neoadjuvant chemotherapy: Results from the NEOZOTAC trial
-
- Assessing treatment effects in older breast cancer patients: Systematic review of observational research methods
-
- Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: Current and future evidence
-
- The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis